These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 15526250)

  • 21. Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria.
    Andersen S; Bröchner-Mortensen J; Parving HH;
    Diabetes Care; 2003 Dec; 26(12):3296-302. PubMed ID: 14633817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations.
    Pohl MA; Blumenthal S; Cordonnier DJ; De Alvaro F; Deferrari G; Eisner G; Esmatjes E; Gilbert RE; Hunsicker LG; de Faria JB; Mangili R; Moore J; Reisin E; Ritz E; Schernthaner G; Spitalewitz S; Tindall H; Rodby RA; Lewis EJ
    J Am Soc Nephrol; 2005 Oct; 16(10):3027-37. PubMed ID: 16120823
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention and treatment of diabetic nephropathy: the program for irbesartan mortality and morbidity evaluation.
    Ravera M; Ratto E; Vettoretti S; Parodi D; Deferrari G
    J Am Soc Nephrol; 2005 Mar; 16 Suppl 1():S48-52. PubMed ID: 15938034
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy.
    Persson F; Rossing P; Hovind P; Stehouwer CD; Schalkwijk C; Tarnow L; Parving HH
    Diabetes; 2006 Dec; 55(12):3550-5. PubMed ID: 17130503
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term effects of Irbesartan treatment and smoking on nucleic acid oxidation in patients with type 2 diabetes and microalbuminuria: an Irbesartan in patients with type 2 diabetes and Microalbuminuria (IRMA 2) substudy.
    Broedbaek K; Henriksen T; Weimann A; Petersen M; Andersen JT; Afzal S; Jimenez-Solem E; Persson F; Parving HH; Rossing P; Poulsen HE
    Diabetes Care; 2011 May; 34(5):1192-8. PubMed ID: 21454798
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension].
    Palmer AJ; Annemans L; Roze S; Lamotte M; Rodby RA; Ritz E
    Dtsch Med Wochenschr; 2004 Jan; 129(1-2):13-8. PubMed ID: 14703575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting.
    Palmer AJ; Annemans L; Roze S; Lamotte M; Rodby RA; Bilous RW
    J Hum Hypertens; 2004 Oct; 18(10):733-8. PubMed ID: 15116142
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings.
    Palmer AJ; Annemans L; Roze S; Lamotte M; Rodby RA; Cordonnier DJ
    Nephrol Dial Transplant; 2003 Oct; 18(10):2059-66. PubMed ID: 13679481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective.
    Coyle D; Rodby R; Soroka S; Levin A; Muirhead N; de Cotret PR; Chen R; Palmer A
    Clin Ther; 2007 Jul; 29(7):1508-23. PubMed ID: 17825702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Irbesartan in hypertensive non-diabetic advanced chronic kidney disease. Comparative study with ACEI].
    Coronel F; Cigarrán S; García-Mena M; Herrero JA; Calvo N; Pérez-Flores I
    Nefrologia; 2008; 28(1):56-60. PubMed ID: 18336132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The protective effect of the RAS inhibitor on diabetic patients with nephropathy in the context of VEGF suppression.
    Chen HB; Lu JX; Li Q; Bao YQ; Tang JL; Lu HJ; Xiang KS; Jia WP
    Acta Pharmacol Sin; 2009 Feb; 30(2):242-50. PubMed ID: 19169272
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Microalbuminuria in hypertensive patients: evaluation of one-year treatment with irbesartan.
    de Alvaro F; Velasco O; Honorato J; Calvo C; Parrondo I;
    Kidney Int Suppl; 2005 Jan; (93):S29-34. PubMed ID: 15613064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy.
    Rodby RA; Chiou CF; Borenstein J; Smitten A; Sengupta N; Palmer AJ; Roze S; Annemans L; Simon TA; Chen RS; Lewis EJ;
    Clin Ther; 2003 Jul; 25(7):2102-19. PubMed ID: 12946554
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Irbesartan prevents the progression of kidney disease or death in patients with type 2 diabetes and high blood pressure.
    Cardiovasc J S Afr; 2001; 12(4):240-1. PubMed ID: 11766617
    [No Abstract]   [Full Text] [Related]  

  • 35. Effects of irbesartan on intracellular antioxidant enzyme expression and activity in adolescents and young adults with early diabetic angiopathy.
    Chiarelli F; Di Marzio D; Santilli F; Mohn A; Blasetti A; Cipollone F; Mezzetti A; Verrotti A
    Diabetes Care; 2005 Jul; 28(7):1690-7. PubMed ID: 15983321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effect of lisinopril on progression of retinopathy and microalbuminuria in normotensive subjects with insulin-dependent diabetes mellitus].
    Sjølie AK; Chaturvedi N; Fuller J
    Ugeskr Laeger; 1999 Feb; 161(7):949-52. PubMed ID: 10051804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria.
    Andersen S; Mischak H; Zürbig P; Parving HH; Rossing P
    BMC Nephrol; 2010 Nov; 11():29. PubMed ID: 21040538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Irbesartan: a review of its use in hypertension and diabetic nephropathy.
    Croom KF; Plosker GL
    Drugs; 2008; 68(11):1543-69. PubMed ID: 18627212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Observational study of blood pressure control and microalbuminuria in type 2 diabetics on irbesartan or irbesartan/HCTZ].
    Schmieder RE; Krekler M
    MMW Fortschr Med; 2005 Oct; 147 Suppl 3():97-101. PubMed ID: 16261944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria.
    Rabbani N; Adaikalakoteswari A; Rossing K; Rossing P; Tarnow L; Parving HH; Thornalley PJ
    Amino Acids; 2012 May; 42(5):1627-39. PubMed ID: 21384133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.